| P2093 | author name string | Daniel E Falk | |
| | Raye Z Litten | |
| | Joanne Fertig | |
| | I-Jen P Castle | |
| | Megan Ryan | |
| P2860 | cites work | Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence | Q37400844 |
| | The effects of varenicline on alcohol seeking and self-administration in baboons. | Q37404736 |
| | Translational strategies for therapeutic development in nicotine addiction: rethinking the conventional bench to bedside approach. | Q37728629 |
| | Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction? | Q38129470 |
| | Neuronal nicotinic acetylcholine receptors are important targets for alcohol reward and dependence | Q38181945 |
| | Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. | Q38405712 |
| | Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. | Q41862387 |
| | Gender differences in response to sertraline pharmacotherapy in Type A alcohol dependence | Q45061459 |
| | Does family history of alcoholism moderate naltrexone's effects on alcohol use? | Q48950377 |
| | Statistics in medicine--reporting of subgroup analyses in clinical trials. | Q51899945 |
| | Psychometric properties of the Penn Alcohol Craving Scale. | Q52277465 |
| | A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence. | Q55057126 |
| | Fluoxetine Treatment Seems to Reduce the Beneficial Effects of Cognitive-Behavioral Therapy in Type B Alcoholics | Q60941447 |
| | Family history and antisocial traits moderate naltrexone's effects on heavy drinking in alcoholics | Q80465926 |
| | Recovery from DSM-IV alcohol dependence: United States, 2001-2002 | Q28236885 |
| | Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors | Q28245329 |
| | The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 | Q29547745 |
| | A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence | Q30412161 |
| | Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking | Q30502320 |
| | Structural differences determine the relative selectivity of nicotinic compounds for native alpha 4 beta 2*-, alpha 6 beta 2*-, alpha 3 beta 4*- and alpha 7-nicotine acetylcholine receptors | Q33770793 |
| | Varenicline reduces alcohol self-administration in heavy-drinking smokers | Q33825408 |
| | Gender differences in public and private drinking contexts: a multi-level GENACIS analysis | Q33965820 |
| | Varenicline decreases alcohol consumption in heavy-drinking smokers | Q34271996 |
| | Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation | Q34565766 |
| | Gender differences in alcohol treatment: an analysis of outcome from the COMBINE study | Q34622414 |
| | Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats | Q35046256 |
| | A double-blind, randomized trial of sertraline for alcohol dependence: moderation by age of onset [corrected] and 5-hydroxytryptamine transporter-linked promoter region genotype | Q35088135 |
| | A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of Type A and Type B alcoholism | Q35354770 |
| | Comparison of alcoholism subtypes as moderators of the response to sertraline treatment | Q35605831 |
| | Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence | Q36133717 |
| | Neuronal nicotinic acetylcholine receptors: neuroplastic changes underlying alcohol and nicotine addictions | Q36137598 |
| | A preliminary investigation of varenicline for heavy drinking smokers | Q36821304 |
| | Relationship between medication adherence and treatment outcomes: the COMBINE study. | Q36952204 |
| | Addiction is a Reward Deficit and Stress Surfeit Disorder | Q37061135 |
| P433 | issue | 4 | |
| P921 | main subject | alcohol dependence | Q4713263 |
| | placebo | Q269829 |
| | varenicline | Q411330 |
| | placebo-controlled trial | Q108853737 |
| P304 | page(s) | 296-303 | |
| P577 | publication date | 2015-07-01 | |
| P1433 | published in | Journal of Addiction Medicine | Q15752435 |
| P1476 | title | Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis | |
| P478 | volume | 9 | |